

CardieX

A Global Health Technology Company
ASX:CDX

Corporate Update
& Overview of Acquisition of

inHealth
medical services

NOVEMBER 2018



STRICTLY CONFIDENTIAL

This presentation has been prepared by Cardiex Limited, (Cardiex or the Company), solely for its use in discussions between the Company and potential investors. The information contained in this presentation is an overview and does not contain all information necessary to make investment decisions. Although reasonable care has been taken to ensure that facts stated in this presentation are accurate and that the opinions expressed are fair and reasonable, no representation, expressed or implied, is made as to the fairness, accuracy, completeness or correctness of the information and opinions contained in this presentation and no reliance should be placed on such information or opinions. This presentation does not constitute an offer, invitation, solicitation or recommendation with respect to the purchase or sale of any security in the Company nor does it constitute financial advice nor take into consideration your investment objectives.

This presentation contains or may contain forward-looking statements that are based on management's belief, assumptions and expectations and on information currently available to management. All statements that are not historical, including those statements that address future operating performance and events or developments that we expect or anticipate will occur in the future, are forward-looking statements. Although management believes these forward-looking statements are fair and reasonable you should not place undue reliance on these statements.

INTRODUCTION

CardieX Limited



CRAIG COOPER – CEO

Australia

Co-Founder - NRG Asia–Pacific – Australia's largest independent energy producer

Senior Associate Lawyer – Blake Dawson Waldron (counsel to United Airlines, The Disney Corporation, DHL International (External General Legal Counsel))

Founder – Private Energy Partners (PEP)

Partner – M-Mobile (largest independent mobile retail distribution company in Australia)

"Craig has built and transformed some of the leading businesses in consumer Internet and digital media. He has a vision for big market opportunities and a passion for living life to the fullest."

Anthony Robbins | Entrepreneur, Author and Peak Performance Strategist

USA

Co-Founder - Boost Mobile USA

Managing Partner – The Action Fund

Investor - The Huffington Post (acquired by AOL), BuzzFeed (USD\$3B), Buddy Media (acquired by Salesforce), Associated Content (acquired by Yahoo), xAD (\$USD1B)

TV Host and Investor – CNBC's "Adventure Capitalists"

Head of Venture Capital and Digital Media – Saban Capital (\$700M)

Founding Partner – Softbank Capital (\$500M)

Venture Partner – VantagePoint Capital Partners (\$3B)

Co-Founder - EBT Mobile (China) LTD



BOARD OF DIRECTORS



Chairman

Donal O'Dwyer

BEng, MBA

Director - Fisher & Paykel (NZE: FPH)

Director - Cochlear Ltd (ASX: COH)

Director - Mesoblast Ltd (NASDAQ: MESO)

Director - NIB Holdings Limited (ASX: NHF)

Cordis Cardiology/Johnson & Johnson

Baxter Healthcare



Executive Director & CEO

Craig R. Cooper

BEC, LLB (Hons)



Non-Executive Director

Niall Cairns

BEC, ACA, FAICD

Managing Partner - Kestrel Capital Pty Limited

Director - Tru-Test Corporation Limited

Chairman - ComOps Limited (ASX: COM)

Director - Chant West Holdings Limited (ASX: CWL)

Managing Partner - Kestrel Growth Funds

Managing Partner - Carnethy Evergreen Fund



Non-Executive Director

R. King Nelson

President and CEO - Uptake Medical Corporation

President and CEO - Kerberos Solution

President and CEO - VenPro Medical

Baxter International, American Hospital Supply

KEY MANAGEMENT



Doug Kurschinski
EVP & Head of Global Sales

(AtCor Medical)
Cardiac Pathways, Corp
St Jude Medical, Corp
Stereotaxis, Corp



Jarrod White
Chief Financial Officer

Traverse Accountants
University of Sydney



ZiHan Lin
Director of Corporate Development

Masimo
Uptake Medical
Cirtec Medical Systems
Harvard (MBA)
Stanford (Engineering)



Rhonda Welch
Reimbursement and Strategic Planning

Biosense Webster
Johnson & Johnson
Baxter Healthcare



Yervant Chijian
Director of Regulatory

Affairs & QA
ResMed
UTS Engineering



Lawrence Chan
Director of Product Development

Cochlear
Silverbrook Research



Ahmad Qasem - PhD
Principal Scientist

PhD - Biomedical Engineering



Lindsey Shultz
Manager - Operations & IT


AWA
Commander
PWV Medical




Mary Hoxworth
Marketing Director

IBM Watson
Pointshare, Corp
Ostex International

CORPORATE HISTORY





BUSINESS OVERVIEW


We provide digital and device based solutions for large scale population health disorders with significant market scale.

- Current focus is on cardiovascular disease (CVD) and heart health - the #1 cause of premature death globally.
- Our long term future lies in developing large scale health technologies in other significant global wellness markets (e.g. obesity, orthopedic health, diabetes management, urology).

Our health solutions and IP have the potential to disrupt multiple multi-billion dollar markets in preventative diagnostics, patient management, wearables, and consumer/digital health.



We provide investment exposure to 3 of the fastest growing global healthcare market opportunities.



OUR MISSION IS
TO CREATE A
SIGNIFICANT AND
VALUABLE
HEALTHCARE
ECOSYSTEM OF
COMPLIMENTARY
PRODUCTS AND
SERVICES




THE PROBLEM

A Global Health Epidemic

Cardiovascular disease is the **#1 killer of humans** by non-natural causes.

- Over **1 billion** hypertensives globally.
- **20M** deaths a year from CVD-related disorders (31% of all global deaths).
- New American Heart Association (AHA) guidelines - **45%** of American adults are now considered at risk for CVD.
- Current embedded technologies (brachial blood pressure cuff) are failing to properly detect, prevent, and manage heart disease - leading to significant under- and over-treatment.
- We need a better way to detect CVD and manage patient health outcomes.



All Cardiovascular Diseases (CVD)

10%	Coronary Heart Disease
9%	Stroke
5%	Other Heart Diseases
2%	Diseases of Arteries, Arterioles & Capillaries
1%	Hypertensive Diseases
1%	Other Diseases of the Circulatory System

OUR SOLUTIONS

Medical Devices - AtCor

Our XCEL SphygmoCor® system allows specialist practitioners, pharmaceutical companies, and research institutions to non-invasively measure central arterial pressure in patients.

Measuring central arterial pressure is the only way to accurately determine and predict pre-hypertension and arterial stiffness - the main precursors to key organ damage and cardiovascular disease.

The XCEL detects key parameters associated with CVD that are usually only detected with an invasive catheter.

- Over **1,000** peer-reviewed studies.
- **4,400** XCEL systems deployed globally.
- The only **FDA 501(k)-cleared** device for sale in the USA deemed to be substantially equivalent to an invasive catheter for all central measurements.
- **CPT 1** reimbursement code.
- Significant IP and patent portfolio.



OUR SOLUTIONS Cont.

Wearable Technologies - Blumio

Financial and Strategic Partnership with Blumio, Inc to Develop Wearable Diagnostic Technologies Based on CardieX IP.

- Silicon Valley based engineering and development team.
- Backed by Peter Thiel (Facebook, PayPal).
- Developer of specialized radar frequency sensors for cardiovascular disease, hypertension, and health monitoring.
- CardieX and Blumio co-developing technologies for cardiovascular and consumer health based on CardieX IP and technologies.
- First phase Macquarie University trial completed.
- Larger scale Deborah Heart and Lung Center trial commenced 30 October, 2018.
- Ambulatory blood pressure monitoring market opportunity - USD\$8b annually.

blumio



SEPARATELY PURSUING

Confidential wearable and licensing technology partnerships with multiple parties.

OUR SOLUTIONS Cont.

TeleHealth - inHealth

Proposed Majority Acquisition of Leading TeleHealth Services Company.

- Leading provider of patient health coaching and Telehealth services.
- Provides digital, eCommerce, and mobile tools for patients to connect online with health coaches as part of a patient care management program.
- inHealth coaching programs based on multi-year published studies that show clinically based health outcomes through the use of inHealth's proprietary health coaching tools.
- \$US25B industry in the USA - growing at a compound rate of 18% per annum.
- Significant contracts with Anthem (NASDAQ:ANTM:US\$70B), the second largest health insurance company in the USA and American Well, the largest Telemedicine provider in the USA.
- Adds significant value to CardieX's healthcare and technology ecosystem.
- Financially accretive and positive to CardieX group in a short timeframe.

Provides a "**direct to consumer**" and "**direct to practitioner**" channel for CardieX products and services and new healthcare initiatives (wearables, medical devices, and digital health).



(see 'Transaction Overview' and more details below)

OUR TECHNOLOGY

& Intellectual Property

- Gold standard **FDA-approved** device for the measurement of blood pressure and cardiovascular risk parameters (Current FDA “predicate device”).
- Current IP and technology focused on cardiovascular health.
- Significant trademarks in consumer and wearable sectors.
- Future applications in “Quantified Athlete”, remote patient monitoring, and broad health categories.
- Proprietary IP & technology in cardiac load, athletic capacity, arterial stiffness, arterial age, and other consumer health diagnostics.
- Expanding licensing and co-development opportunities in broad medical health and consumer segments.
- Over 1000 published **peer-reviewed** studies.
- 13 USA patents covering significant applications in cardiovascular health and consumer wearables.

1939

Hypertension

1961

Elevated
Cholesterol

TODAY

Arterial
Stiffness
PWV




Pulse Wave Velocity

(PWV) is the most research supported method to assess arterial stiffness in order to improve cardiovascular risk prediction (American Heart Association, American College of Cardiology). **CardieX's XCEL** is the the most clinically validated, peer viewed, and study based technology for measuring PWV.

HOW WE CURRENTLY MAKE MONEY

We sell/lease the XCEL and related products to:



FUTURE REVENUE DRIVERS

Multiple revenue opportunities driven by an ecosystem of complementary healthcare assets and sales channels



Medical Devices

- Sale and lease of medical devices to health professionals.
- Clinical trial services.
- IP licensing (SunTech).
- Distribution partnership fees (Asia-Pacific, China, and Europe).
- Direct/online device sales.



Wearable Consumer and Medical Technologies

- IP licensing.
- "Reference design" sales to wearable and consumer device companies (Apple/Fitbit/Garmin).
- Direct product sales of CardieX cardiovascular health wearables.
- Co-development revenues from jointly developed Blumio/CardieX products and IP.



Digital and Consumer Health

- Patient health coaching fees (Anthem/American Well etc).
- Consumer health product sales.
- Sale of nutritional and health coaching programs (devices, meal plans, supplements).
- "Direct to patient" consumer program sales.
- "Direct to practitioner" program sales.
- inHealth program licensing to wearable and consumer health companies (Apple/Fitbit/Garmin).
- Mobile app sales.



New Product Development

- Commercial in confidence development of new products and services for USA and Chinese medical and consumer markets.
- Current focus on commercialization of CardieX IP in new devices and technologies.

OUR 2019 PLAN

Three new growth, product, and revenue platforms +
New China Strategy

DIRECT TO PRACTITIONER

- Newly rebranded and **customizable** XCEL SphygmoCor® (V.2) allows sales to multiple markets (consumer/health practitioner/specialist) with a single product at variable price points.
- Expanding our core technology and products to a broader health practitioner market (1M+ licensed MDs and 30K naturopathic professionals in the USA) - a 30x increase in our current addressable market.
- Enabling health practitioners to create new significant revenue streams (turning a **non-billable** event into a **billable event** by using our CPT 1 reimbursement code).
- Direct-to-practitioner marketing and training using online and direct sales channels.
- Sales focus built around a multi-platform health management + lifestyle program w/ CardieX App.
- Expand CPT reimbursement program from (current) 46% USA coverage.



\$5B Total Addressable Market Opportunity

30,000
Specialists
(Cardiologists, Nephrologists)

1M+
MDs/Licensed Health Practitioners

30X in our addressable sales market



WEARABLES AND DEVICES



- Co-developing a sensor-based consumer blood pressure wearable incorporating artificial intelligence (A.I.) and CardieX intellectual property - a USD\$7.5B global market opportunity.
- Developing a suite of A.I.-based consumer data applications for licensing to device manufacturers/OEMs (i.e. Apple) for “cardiac load” and “exercise capacity”.
- Co-developing a wearable ambulatory 24-hour ABPM that measures BP and cBP (a USD\$8B global market opportunity).

USD\$8B+
Global Market Opportunity



CONSUMER & DIGITAL HEALTH

- Enabling consumers to directly manage their health through **direct-to-consumer** digital products, patient health coaching, and technologies that drive **behavioral change** (target market - over 1 billion hypertensive humans globally).
- Expanding the inHealth Telehealth programs to encompass solutions for hypertension, and other major global health disorders.
- Establishing OEM partnerships for branded consumer blood pressure monitoring devices.
- Currently in due diligence on multiple strategic opportunities.

1B Hypertensives
Globally




At home blood pressure monitoring expected to reach

USD\$1.6B

globally by 2023 (IEEE)

CHINA STRATEGY

Reassess existing distribution + build new partnerships + establish local entity + new product development



TRANSACTION OVERVIEW

CardieX + inHealth



INHEALTH

Business & Market Overview

- Leading provider of digital patient health coaching and Telehealth services.
- Provides digital, eCommerce, and mobile tools for patients to connect online with health coaches as part of a patient care management program.
- inHealth's programs based on multi-year published studies that show clinically based health outcomes through the use of inHealth's proprietary health management tools.
- Telehealth solutions being accelerated Nationwide by hospitals (over 50% of US hospitals are currently deploying Telehealth), insurance payers (Anthem), employers, and through direct-to-patient platforms (American Well).
- Telehealth also rapidly being integrated across devices that provide Patient Generated Health Data ("PGHD" - Fitbit/Apple Watch/ home health devices such as blood pressure monitors).
- Telehealth seen as a critical part of the next generation healthcare ecosystem in order to reduce insurance payer costs and drive better health outcomes for patients.




Aubrey Jenkins
CEO and Co-Founder



Michelle Alencar
CSO and Co-Founder

11 Fulltime Employees, 35 Active + 170 (pre-screened) Telehealth Coaches

Telehealth Size & Growth Rate



HEALTH COACHING IS THE MISSING LINK IN THE HEALTHCARE CHAIN

Any device that "mines" patient generated health data ("PGHD") requires a Telehealth solution.

Data Mining Devices

- zzz Fitbit (Sleep & Weight Loss)
- Garmin (Stress)
- ZIO (Arrhythmia)
- Blumio (Blood pressure)
- AtCor XCEL (Blood pressure)
- Apple Watch (EKG)
- Dexcom (Diabetes)



Telehealth Coaching

inHealth provides the crucial link between data and diagnostics, and better patient outcomes.



Connected Devices

- Amazon Alexa
- Google Home
- Apple HomePod

Apple logo
"Hey Siri, how can I lose weight?"

Amazon logo
"Alexa how can I reduce my blood sugar?"

ACQUISITION OF INHEALTH MEDICAL

Transaction Overview

A strategic and value add transaction that multiplies the value of the CardieX Group assets and business operations.

- Acquisition of 50.5% of an established "direct-to-patient" online health platform with leading insurance groups, health professionals, and corporate/employer payer groups as existing customers.
- Transaction provides for CardieX to gain operational and financial control through a series of staged investments through 2020.
- Direct relationships with Fortune 500 companies and leading companies in the USA healthcare ecosystem.
- Multi-year contracts with significant USA healthcare companies driving accelerated revenue growth (Anthem (#2 USA health insurance company - US\$74B) & American Well (#1 USA Telemedicine platform).
- Major business and corporate deal pipeline with leading companies in consumer goods, pharmaceutical companies, and healthcare providers.
- Value driven acquisition forecast to contribute to CardieX revenue and profitability in a short time frame - inHealth revenues growing strongly and forecast to become profitable in 2019.
- inHealth business model based on immediate multi-tier revenue structures in one of the fastest growing health technology sectors.
- Strong synergy with CardieX existing business operations.

INHEALTH CUSTOMIZED PROGRAMS

inHealth programs are designed to empower providers, drive practice revenue, & help patients meet their health goals.




Weight Loss

Multidisciplinary Weight Loss programs focusing on Nutrition, Behavior and Fitness. 9 different protocols offered.




Chronic Care Management

Medicare and commercial payers want you to offer CCM. We are here to help.



Diabetes Prevention

inHealth offers certified diabetes prevention dietitians & programs. Recognized DPRP organization



Sport Nutrition

Expert protocols for maximum performance Diet analysis services that include complete sports analysis.

LAUNCHING 2019

Hypertension, Sleep, Mental Health

SAMPLE INHEALTH PROGRAMS

inHealth programs are designed to empower providers, drive practice revenue, & help patients meet their health goals.



SAMPLE INHEALTH PROGRAMS Cont.

Don't Get Left Behind!

Payers, providers, employers and other health industry professionals are increasingly looking to telemedicine as a low-cost and effective option to improve health outcomes. The telemedicine market is expected to grow at a compound annual growth rate of more than 18% by 2020.¹ inHealth can help close the gap between technology adopters and innovators so everyone wins!

Steps to Get Started

1

Consider your goals and timeline

Let us guide you through the process of setting goals for your organization and preparing a timeline for launch.

2

Training and implementation

Our comprehensive implementation and training process should take anywhere from two weeks to two months depending on the project.

3

Get the word out

inHealth will provide initial and ongoing marketing support to help get the word out to your customers.

4

GO LIVE

1-888-219-5299 | info@inhealthonline.com | www.inhealthonline.com | 1801 Century Park East, 24th Floor, Los Angeles, CA 90067

1-888-219-5299 | info@inhealthonline.com | www.inhealthonline.com | 1801 Century Park East, 24th Floor, Los Angeles, CA 90067

1-888-219-5299 | info@inhealthonline.com | www.inhealthonline.com | 1801 Century Park East, 24th Floor, Los Angeles, CA 90067

Engagement Matters

A CLINICAL SERVICES COMPANY DELIVERING Virtual Health Coach Staffing & Training, Ancillary Care Program Development, & Clinical Research in the Health Tech Space

Why our services are critical to payers, providers, and technology companies

Reduce payer cost

- Business-to-business model that connects patients to the tools and support they need for easy adoption of technology-based health care
- Improve patient outcomes and decrease risk factors, resulting in lower cost

Create a profitable provider extension

- Weekly health coaching and ancillary care treatment between office visits
- A full team approach without the cost of developing it yourself

Increase utilization of technology

- One-stop-shop solutions that close the gap between payers, providers and technology companies
- Customized ancillary care programs developed for technology platform integration
- Seamless deployment of technology platforms through integrated programs and support

- Seamless deployment of technology platforms through integrated programs and support
- Customized ancillary care programs developed for technology platform integration
- One-stop-shop solutions that close the gap between payers, providers and technology companies
- Increase utilization of technology

- A full team approach without the cost of developing it yourself
- Weekly health coaching and ancillary care treatment between office visits

The Mobile App: You're In Control

Our health tracking features within the HEALTHIE app put you in charge of your health while keeping your healthcare provider informed of your activities, progress toward goals and vital signs.

Here are just a few of our app features:

- Monitor vitals like blood pressure, blood glucose levels, and weight
- Establish health and fitness goals that make sense
- Track progress toward goals
- Securely share medical records with any practice

ENJOY LIVE VISITS THROUGH YOUR HANDHELD DEVICE!

How Can I Get Started?

Ask your healthcare provider for details on how you can get started today!

It's easy as 1, 2, 3!

1

Speak to your healthcare provider about getting started

2

Download the mobile app and enter practice code: INHEALTH

3

Meet your new health coach and start your journey to a happier, healthier life

1-888-219-5299 | info@inhealthonline.com
www.inhealthonline.com

www.inhealthonline.com
1-888-219-5299 | info@inhealthonline.com

www.inhealthonline.com
1-888-219-5299 | info@inhealthonline.com

Take Your Healthcare Team with You

Weight Loss / Chronic Disease Management / Diabetes Prevention / Sport Nutrition

Most commercial PPO and Medicare plans accepted.


www.inhealthonline.com
1-888-219-5299 | info@inhealthonline.com

www.inhealthonline.com
1-888-219-5299 | info@inhealthonline.com

29

CURRENT

Corporate Telehealth Business Pipeline*



*via American Well partnership.

Plus > 2M DTC Enrollments

INHEALTH KEY BUSINESS OPERATING SEGMENTS



```
graph LR; A((INHEALTH KEY BUSINESS OPERATING SEGMENTS)) --- B((INSURANCE PAYERS)); A --- C((TELEMEDICINE PROVIDERS)); A --- D((CORPORATE WELLNESS PROGRAMS)); A --- E((PRIVATE PRACTICE)); A --- F((DIRECT TO PATIENT))
```

**INSURANCE
PAYERS**

**TELEMEDICINE
PROVIDERS**

**CORPORATE
WELLNESS
PROGRAMS**


**PRIVATE
PRACTICE**

**DIRECT TO
PATIENT**

INSURANCE PAYERS

Anthem (#2 US health insurance company)


- 3 year contract with extensions to provide Telehealth services to Anthem's National client base.
- Anthem sells inHealth's Telehealth program to their employer customer base to offer to employees.
- inHealth receives payment based on time spent in "session" - average \$41 per patient.



TELEMEDICINE PLATFORMS

American Well ("Amwell") (#1 USA Telemedicine Platform)


- Annual automatically renewable contract to provide Telehealth services to Amwell's customer base.
- Clients pay Amwell but multiple parties pay inHealth depending on the nature of the service.



SPECIALIST WELLNESS PROGRAMS


and Corporate Health Plan Providers

- Multiple RPF's in development and significant business pipeline with pharmaceutical and consumer goods companies and specialist medical practice chains (e.g. Bariatric Advantage).
- Patients pay Providers directly depending on program but multiple parties pay inHealth for products and services.




PRIVATE PRACTICE

- Existing business operations and current inHealth revenues driven principally by direct Telehealth programs offered by individual practitioners.
- Multiple parties pay inHealth for Telehealth services and for product purchases.



DIRECT TO PATIENT

inHealth and CardieX jointly owned health programs marketed "direct-to-patient" through digital, online and consumer marketing programs.



STRATEGIC VALUE

of inHealth to CardieX Group

- Strongly positions CardieX in the high growth digital and consumer Telehealth sector.
- Provides CardieX's core technology with direct channels to both the consumer, health insurance, and practitioner markets.
- Positions CardieX (via inHealth) with leading US health insurance companies and healthcare providers with multi-year contracts (Anthem & American Well) - each of which have stated strong growth intentions for the respective partnerships.
- Provides a platform for the development and sale of insurance backed technology solutions covering multiple health disorders (e.g. heart health, hypertension, sleep) that can be sold through inHealth's existing insurance and partner network and business pipeline.

"Any device or platform in the future that provides personal health generated data ("PHGD") will require a Telehealth component in order to maximize patient outcomes"



Our vision is to build the largest global Telehealth company with multiple product and service offerings across the healthcare sector. inHealth is our platform for executing this vision.

- Creates an "in-house" clinical trial group within CardieX that can cost effectively run and manage clinical trials for CardieX group products.
- Key executive "C suite" relationships across the chain of the US healthcare system.
- An existing suite of proprietary healthcare products and services that can be rapidly deployed into the corporate wellness sector as well as across multiple global markets including, and as a priority, China.
- A direct and online channel for sale of CardieX group products (Blumio wearable technology and CardieX's XCEL device).
- Partnership opportunities to provide turnkey Telehealth management programs to the next generation of healthcare providers that need patient care services including Apple (Apple Health "click to connect"), Alibaba and SoftBank (recently announced health platforms), Amazon (Alexa Health), and Google (Health Services Group).

CARDIEX + INHEALTH

Financial Transaction Summary



Highlights

- Three (3) tranches of investment under executed Convertible Note for 50.5% of inHealth.
- First tranche paid with existing cash reserves.
- CardieX maintains operating and financial control through all stages due to "Consent Rights".
- Effective \$USD5M pre-money valuation of inHealth on full investment (assuming purchase of founder shares in tranche 3).
- Approximately \$USD5M total cumulative investment over the period of the Note(s).

Transaction Summary

Tranche	Instrument	Date of Investment	Maturity Date	Investment (\$)	Equity % in inHealth	Cumulative Equity % in inHealth
1	Convertible Note	15 October 2018	31 January 2019	US\$250,000	7.7%	7.7%
2	Convertible Note	31 January 2019	1 July 2020	US\$3,000,000	33.33%	41.33%
3.A	Convertible Note	Between: 30 June 2020 to 30 June 2021	30 June 2021	US\$ amount of 12 times the revenue for the 3 calendar months preceding the exercise; or as at 31 December 2020 if the exercise date is earlier. (~3x annual revenue run-rate)	9.467%	50.5%
OR						
3.B	An option to acquire shares from the inHealth founders	Anytime	Anytime	US\$ amount of 12 times the revenue for the 3 calendar months preceding the exercise; or as at 31 December 2020 if the exercise date is earlier. (~3x annual revenue run-rate)	9.467%	50.5%

FINANCIAL BENEFIT

of Transaction to CardieX



inHealth's business model is based on multiple revenue streams that are financially accretive to CardieX in a short time frame.

If we execute to plan and meet 70% of our projections inHealth will be a bigger revenue business than our current "AtCor Medical" device business by this time next year and be profitable - and will be 2x the size of AtCor's current business on a revenue basis by 2020.

Targeted Customer Revenue Events

		Base	Base * 2	Base * 3
Insurance		45000	90000	135000
TeleHealth		15000	30000	45000
Corporate		10000	20000	30000
Direct to Physician		7000	14000	21000

	Average Revenue Per Customer Event (USD)	Indicative Revenue (USD)		
Insurance	40	\$1,800,000	\$3,600,000	\$5,400,000
TeleHealth	65	\$975,000	\$1,950,000	\$2,925,000
Corporate	50	\$500,000	\$1,000,000	\$1,500,000
Direct to Physician	38	\$266,000	\$532,000	\$798,000
Total Illustrative Revenue		\$3,541,000	\$7,082,000	\$10,623,000

Less direct variable costs

Insurance	51%	\$921,951	\$1,843,902	\$2,765,854
TeleHealth	19%	\$184,477	\$368,954	\$553,432
Corporate	51%	\$255,654	\$511,309	\$766,963
Direct to Physician	58%	\$154,670	\$309,341	\$464,011
Total Direct Variable costs		\$1,516,753	\$3,033,507	\$4,550,260
Gross Margin		\$2,024,247	\$4,048,493	\$6,072,740

CDX TODAY

17%

Director
Shareholdings

531,018,794

Shares on issue




\$19,647,695

Market Cap

\$0.037




Current Price



83.36%

Free Float



44.62%

Top 20 Shareholders

2019
(Forecasted)

2018
(Actual)

2017
(Actual)

\$4,221,670

\$4,006,091

\$4,327,283

Revenues (\$AUD)

THANK YOU

CONTACT

Craig Cooper
CEO - CardieX
ccooper@cardiex.com
0429 993 399

